Thank and earnings everyone. good you, Scott update. to XXXX morning our quarter Welcome corporate second call
lives market fluid be management become forefront is in vision overload. change fluid patients suffering when diuretics management that Solutions leader global from CHF continues the have patients heart to failure of Our of the to in failed. fluid with solutions the at
in update call, two, following made number clinical During growth; accounts on and studies. the and I the update four to expected be I in strategy hospital new will executing vision. on will the our progress revenue in five, on provide cardiovascular update; QX finally surgery highlight pediatric an QX; opened update three, one, topics; accounts have we QX opened in
metric important execution successful most is growth. the Today demonstrating revenue
representing million Aquadex XX% X.X XXXX. Sequentially, in XX% year-over-year double technology was XXXX, since quarters increase revenue increased growth consecutive QX Second the a year-over-year acquired in versus digit quarter from revenue we QX XXXX. nine revenue of
clinical direct international investment the our of and our result commercialization a continued is growth making US the revenue are and team, successful organization. therapy we us Our of team sales support our of our the strategy execution distributor in expansion
margins in As again our the manufacturing are second we achieving gross seeing internal improvements volumes increase, quarter. continue our XX% in to
Heart in the Delaware. at Healthcare and as Institute accounts, St. in several we that hospital During both Hospital opened Francis, Beebe well quarter, announced new we Oklahoma, Oklahoma Tulsa, had as Heart including
St. BayCare in in which Johnson we several Health Centre and addition, opened St. systems, Medical Florida, new and Wilson Hospitals City, accounts Petersburg, hospital York. Raleigh, Carolina, In announced, and UHS in including not North Hospital health New Anthony's we yet WakeMed have
also Thomas Hospital several in Elkhart, Jacksonville We that University reactivated Aquadex Philadelphia, Florida. of including Jefferson Jacksonville, ownership, institutions Chad's General in Elkhart in Indiana, Hospital and had use Medical under Baxter's discontinued Centre the
Looking Health Scott is forward of for University in Hospital which North XX systems initiating in Heart health to Resources a hospital in system the Hospital Hospital represents provider Texas White DuPont Aquadex Memorial that QX, with of Texas QX XX care the patients and and well Bend, Wilmington, Austin, have Texas, Tennessee, South need in in Memphis, St. the other in throughout Hospital Baylor & robust we largest in any System, System, Houston, the in Health which including locations. and Methodist than therapy, Hermann Vascular hospitals cares pipeline Texas Hospital Indiana, Cleveland, Texas. Texas Children's Memphis, Hospital Houston, as Delaware, and Methodist Texas, Hospital area, as more Joseph
to we're decided our have to additional growth. accounts opening our the quarters in organization numerous support Given we – pipeline expand coming systems strong and to make field investments hospital with
five training During specialists accounts specialists of educating clinical has to and in from increased number play new Clinical once adoption the account on been proper in the open. an therapy therapy QX of the important XX. the driving education use we and role in
any in to surgeon, the ultra-filtration and mortality our growth FlexFlow form including prescribed therapy of intensivist use our rates. diuretics, many of is scores On who system cardiovascular because The and hit surgery needed for costs ICU involved cardiovascular from excess quality of decrease care by can and penalties. without responding in thus volume undergone be of be potential cardiovascular are of avoiding in the assistant. specialty the the the prescribed the opportunity Aquadex patients and decisions removal expedite significant pulmonologist, and can front, is a have overload that critical ventilator, from who potential by Removing the nephrologist is the discharged surgery calling treatment patients medical a patients not in anesthesiologist, for to care physician's simple the surgery fluid
doctors Dr. American during The surgeon surgery. Canada, cardiac Thoracic Medical at Aquadex improving May, on Centre City, key to Hospital Baltimore, for risks session meeting our Toronto, help in use M.D., Daniel on was Maryland. of Annual with reasons Surgery Beckles, post in the cited panel Israel and attended patients. on moderated from Among we Mehdi discussion from thoracic panel Association device Health the associated staff, rapid Systems hospital with FlexFlow In for mortality, highlighted hospital removal individual decrease need. efficient and in Dr. where of in York the use of Franklin the patient Oloomi New renowned of ease a members and included and Mark Small personalized in the using both, New patients a the based the by cardiothoracic the Jersey, sponsored fluid from surgery the from resources Margarita our for Camacho overload other Sinai physician treatment session outcomes Square Newark ability system Ph.D., manage ventilator, Mount Medstar were Beth The clinical a we aquapheresis utilization assistant
the of the be meeting Aquadex the participated day Failure American American treatment heart to Heart patients, In of we CHF leads Solutions of it that June, FlexFlow is heart including Austin, continues system. annual in as Nurses for Heart Failure Association failure the important day failure nurse in venue often an to Association the Nurses, operation The Texas. of XXth
to therapy and clinical the rate individual training meet the have focused the to to fluid safe ability which therapy. with each clinical unpredictable ensure to a using sharp adjust diuretic our delivery results patient's contrast needs, precise We removal of is the
label strategy successful pre-submission very a had patients. agreed we application the to strategy, specifically with very to May collaborative presented. The mid in meeting was of pediatric our our modifications FDA XXX(k) Regarding supportive, the pediatric FDA we include with and discuss
we meaning the safety pediatric for any evaluations submission FDA tests the recommended FDA XXX(k). clinical the did several not complete additional bench to before pre-submission of additional the population. require The During confirm
XXXX I we anticipate in call, As expanded have second our the quarter will half pediatrics XXXX. XXX(k) clearance use first for of in reported earnings
continue treating marketing We inquiries to receive physicians from pediatric unsolicited pediatric currently patients, but to not are hospitals.
for capabilities system pediatric patients low blood These therapy, membrane with of because oxygenation heart the leading fluid small are therapy its replacement including patients and extracorporeal available surgery, Aquadex capability. organ and that six cardiac fact is this kidney children's conditions use hospitals of disease, required the volume to can patients In country's for children's Aquadex overload, size hospitals only treat result with by treating pediatric extracorporeal device many transplant.
On the and the published clinical underway we to several studies studies expect front, be are there months. next XX three to results in
synergies clinical identifying results. importantly between management volume therapy. researching to and the more and on manage We and to to initiated that treatment diagnostic Daxor system, to important collaboration when providers believe to building Corporation status, how and Volume is multiple evaluation therapy, Aquadex remain selection, FlexFlow diagnostics strategy we positive with Daxor when Blood fluid evaluate Analyzer document Aquadex appropriate therapy maximize technologies ultrafiltration. to the throughout a manage BVA-XXX patient may our how assist clinical fluid focused on tools with clearly the that another discontinue initiate refine on We companies to this to First, of Daxor's block therapy clinicians which achieve inform
the hospitals Daxor clinical to initiated on clinical we're working several with evaluation, studies. In addition physician
clinical and controlled evaluated, Sinai retrospective cardiac total that who in in their match and Aquadex that XXX results XXX use We New of will assess Hospital did be A are York Mount surgery XXX support working and will not with patients cases. the to study underwent that patients of associated outcomes. filtration the
with the fluid which the a of Hospital XXX readmission patients, rates retrospective ultrafiltration. Jefferson post define Health on has the study renal function part Philadelphia in of aim to outcomes with Abington and approved amounts Additionally, impact removal, is system
QX, treat that a we wants City with use institution prominent to York Aquadex liver advanced in in addition, to In discussions patients. New their disease initiated
indication to have next to more news potential this share call. will our on regards with We
sales IV an to the ourselves challenges and ultrafiltration Given reduce introducing major as re-hospitalization provider continuing the cardiac of intensivist clinical commercialization for current value outcomes, therapy surgeons. awareness of market further hospitals, the healthcare the cardiologists, grow our expense to of efforts the opportunity expanded improve accelerated the to by as the using and system. growing only, ultrafiltration diuretic in spearheading and primary clinical therapy thereby anticipate worldwide reduce with rates We're faced treatment we position
QX now financial the and over I to who our turn will walk can details. call results you through XXXX Claudia,
questions. some provide and closing call will I that to open comments the Following
